Maze Therapeutics, Inc.
MAZE
$41.49
$4.2211.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.06% | 6.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.62% | 3.03% | |||
| Operating Income | 9.62% | -3.03% | |||
| Income Before Tax | 10.67% | -2.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 10.67% | -2.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.67% | -2.72% | |||
| EBIT | 9.62% | -3.03% | |||
| EBITDA | 9.58% | -3.19% | |||
| EPS Basic | 14.54% | 32.85% | |||
| Normalized Basic EPS | 14.52% | 32.86% | |||
| EPS Diluted | 14.29% | 32.76% | |||
| Normalized Diluted EPS | 14.52% | 32.86% | |||
| Average Basic Shares Outstanding | 4.53% | 52.99% | |||
| Average Diluted Shares Outstanding | 4.53% | 52.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||